论文部分内容阅读
糖尿病人存在着明显的血小板功能亢进,血小板的活化易引起微血栓的形成,进而导致微血管病变,是糖尿病人病情发展的一大特征。能够抑制血小板活化,延缓微血管病变,对于延长糖尿病人的生命意义重大。阿斯匹林(ASA)是抑制血小板活化的常用药物,本文观察Ⅱ型糖尿病患者(NIDDM)服用ASA前后血小板数目及血小板膜表面GMP-140(GMP-140)水平变化,以探讨ASA对糖尿病微血管病变者血小板功能的影响。 材料和方法 一、对象: (一)NIDDM患者106例,依据1980年WHO制定糖尿病诊断标准。有微血管病变者诊断依据:①1984年10月第三届全国眼科学术会议制订眼底分级标准,眼底镜观察方糖尿病视网膜病变者。②放射
Diabetes patients have obvious platelet function hyperthyroidism, platelet activation easily lead to the formation of micro-thrombus, which led to microvascular disease, is a major feature of the development of diabetic patients. Can inhibit platelet activation, delay microangiopathy, to extend the life of people with diabetes is of great significance. Aspirin (ASA) is a commonly used drug that inhibits platelet activation. We observed the changes of platelet count and GMP-140 (GMP-140) level before and after ASD in patients with type 2 diabetes mellitus (NIDDM) The impact of platelet function in patients with lesions. Materials and methods First, the object: (a) 106 cases of NIDDM patients, based on the 1980 WHO to develop diabetes diagnostic criteria. The diagnosis of microvascular lesions are based on: ① October 1984 the Third National Eye Academic Conference to develop fundus grading standards, ophthalmoscopy observed diabetic retinopathy. ② radiation